On September 27, 2023 Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, reported that six abstracts highlighting its broad pipeline of clinical and preclinical product candidates as well as a shortened TIL manufacturing process have been accepted for presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) taking place in San Diego, Nov. 1-5, 2023 (Press release, Lyell Immunopharma, SEP 27, 2023, View Source [SID1234635454]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Our presentations at SITC (Free SITC Whitepaper) highlight the progress we are making on several fronts to advance new product candidates and technologies designed to generate potent and durable cell therapies for patients with solid tumors," stated Dr. Gary Lee, chief scientific officer at Lyell. "At SITC (Free SITC Whitepaper), we look forward to sharing new preclinical findings on product candidates and emerging technologies, data on our Epi-R P2 manufacturing process which is designed to shorten TIL product delivery time to patients, and highlighting the design of our two ongoing Phase 1 clinical trials in progress."
Four presentations highlight new nonclinical data from pipeline product candidates and research programs, including a new technology being advanced through a collaboration with Outpace to enable context-dependent, localized IL-12 activity to enhance solid tumor T cell therapies; and Lyell’s novel Epi-R P2 manufacturing process to shorten manufacturing time for tumor infiltrating lymphocyte (TIL) therapy.
Two additional presentations highlight the design of Lyell’s ongoing Phase 1 clinical trials in progress: LYL797, a ROR1-targeted CAR T-cell therapy being evaluated in a Phase 1 trial in patients with relapsed refractory triple-negative breast cancer and non-small cell lung cancer, and LYL845, a tumor infiltrating lymphocyte (TIL) therapy being evaluated in a Phase 1 trial in advanced solid tumors.
Details on the six poster presentations are below:
Epi-R P2 protocol produces a scalable polyclonal TIL product with a greater expansion success rate across hot and cold tumors in shorter culture time
Presentation Date & Time: Friday, Nov. 3, 12–1:30 p.m. and 5:10–6:40 p.m.
Abstract Number: 379
Preclinical development of LYL119, a ROR1-targeted CAR T-cell product incorporating four novel T-cell reprogramming technologies to overcome barriers to effective cell therapy for solid tumors
Presentation Date & Time: Saturday, Nov. 4, 2023, 11:55–1:25 p.m. and 7–8:30 p.m.
Abstract No.: 278
Protein design and inducible expression allow context-dependent, localized IL-12 activity to enhance solid tumor T cell therapies
Presentation Date & Time: Friday, Nov. 3, 12–1:30 p.m. and 5:10–6:40 p.m.
Abstract No.: 1047
Rejuvenation of tumor-infiltrating lymphocytes (TIL) through Partial Reprogramming
Presentation Date & Time: Friday, Nov. 3, 2023, 12–1:30 p.m. and 5:10–6:40 p.m.
Abstract No.: 393
Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic reprogramming, in advanced triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC)
Presentation Date & Time: Saturday, Nov. 4, 2023, 11:55–1:25 p.m. and 7–8:30 p.m.
Abstract Number: 754
Phase 1 trial of LYL845, an autologous tumor-infiltrating lymphocyte (TIL) therapy enhanced with epigenetic reprogramming, for the treatment of advanced solid tumors
Presentation Date & Time: Friday, Nov. 3, 2023, 12–1:30 p.m. and 5:10–6:40 p.m.
Abstract No.: 747